Opthea: Developing novel therapies for the treatment of eye diseases.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Opthea: Developing novel therapies for the treatment of eye diseases.
Released on: December 06, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak.
  • Summary
  • Participants
  • Company
Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD). Fintan Walton, CEO of PharmaVentures talks with Megan Baldwin, Managing Director & CEO, about how Opthea is currently investigating OPT-302 in an ongoing Phase 1/2A clinical trial in wet AMD patients.
Dr Megan Baldwin, Managing Director & CEO, Opthea
Opthea's technology is centred on VEGF-C, VEGF-D and VEGFR-3. VEGF-C and VEGF-D promote blood and lymphatic vessel development. VEGF-C also causes vessels to leak. OPT-302 blocks the activity of VEGF-C and VEGF-D and is being developed for the treatment of wet AMD, the leading cause of blindness in the Western world. Wet AMD is characterised by loss of vision in the centre of the visual field and is caused by the abnormal growth and leakage of vessels at the back of the eye. Blocking the signals that lead to this abnormal vessel growth and vascular leakage has the potential to improve patients' vision. Since its inception, RHS has maintained a consistent focus on improving health and research outcomes and has built an experienced team and significant know-how in the development of whole genome amplification and array Comparative Genomic Hybridisation tools. It is this expertise that has gone into RHS’s EmbryoCellect™ kit. RHS is located in the Bio Innovation SA Incubator in the heart of the Thebarton biotechnology precinct in Adelaide, South Australia. The company is listed on the Australian Stock Exchange (ASX).